Colin Havenar-Daughton | Director of Immunology
Vir Biotechnology

Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

Colin Havenar-Daughton is a Director of Immunology at Vir Biotechnology. He earned his PhD degree in Immunology from the University of Washington. Colin conducted postdoctoral studies in Shane Crotty’s laboratory at the La Jolla Institute, where he focused on the immunological underpinnings of vaccination and applied these learnings to HIV vaccine development. At Vir, he aims to contribute to the development novel therapeutic and prophylactic medicines for a wide array of infectious diseases including SARS-CoV2, influenza, HBV, and HIV.


WVIC/WAC Pre-Congress Workshops - Nov 28 @ 14:00

Workshop B [Room: Constellation B]

Antibody Drug Discovery for Infectious Diseases

2pm – 5pm

2pm: Chair opening remarks: Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

Presentations 2.10pm – 4pm:

Shark-derived nanobodies for diagnostic and therapeutic use

Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine

Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases

Dr Sha Ha, VP, CMC, IGM Biosciences

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants 

Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus

Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology, LaJolla Institute

Tackling viral infections by human monoclonal antibodies

Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection

  • How to develop antibodies that are resistant to viral mutations? 
  • How can the cost be justified if other therapeutics are available?
  • What effects has the pandemic had in increasing desire for therapeutic antibodies
  • The role of FC and FC modifications to enhance effector function
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall